Topical mupirocin versus topical neosporin in the treatment of cutaneous infections.
Wilkinson
R D
RD
Department of Dermatology, Royal Victoria Hospital, Montreal, Quebed, Canada.
Carey
W D
WD
D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001414:Bacitracin / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D005227:Fatty Acids / Q000008:administration & dosage; D006801:Humans; D016712:Mupirocin; D009355:Neomycin / Q000008:administration & dosage*; D011112:Polymyxin B / Q000008:administration & dosage*; D011113:Polymyxins / Q000008:administration & dosage*; D011897:Random Allocation; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000209:etiology; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology; D013210:Staphylococcus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005227:Fatty Acids; D011113:Polymyxins; D001414:Bacitracin; C001816:bacitracin zinc, neomycin sulfate, polymyxin B, drug combination; D016712:Mupirocin; D009355:Neomycin; D011112:Polymyxin B